Piper Sandler reiterates Climb Bio stock rating after ASN data By Investing.com

BTIG Reiterates Buy on Climb Bio, Maintains $32 Price Target

CLYM 8-K & SEC Filings

Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $25

Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

One patient with kidney disease had 3 years of remission without steroids

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio, Inc. Estimates – NASDAQ:CLYM

Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027

CLYM Dec 2026 20.000 call (CLYM261218C00020000) stock price, news, quote and history

Joe Cotton’s Weekly Stock Picks: Speculative biotechs — Faeth Therapeutics and Climb bio

Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline

Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28

Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?